Fig 1: The expression of IL-37 protein in different stages of carcinogenesis tissues.(a) Immunohistochemical analysis of IL-37 expression in human healthy oral mucosa, OLK and OSCC lesions. (b) Comparison of the staining score between these groups (***P < 0.001).
Fig 2: The expression level of the IL-37 receptor IL-18Rα and binding partner IL-18BP in NC, OLK and OSCC tissues.(a) Immunohistochemical analysis of IL-18Rα and IL-18BP expression in NC, OLK and OSCC tissues. (b) Comparison of the staining score between these groups (*P < 0.05, **P < 0.01).
Fig 3: Relationship between IL-37 expression level and the degree of epithelial dysplasia in patients with OLK.(a) Immunohistochemical analysis of IL-37b expression in OLK lesions without epithelial dysplasia (top panels), with mild dysplasia (middle panels) and with moderate dysplasia (bottom panels). (b) Comparison of the staining score between these groups (***P < 0.001).
Fig 4: The expression of IL-37 in OSCC with or without metastasis ability.(a) Immunohistochemical analysis of IL-37b expression in OSCC patients with/without metastasis. (b) Comparison of the staining score between the two groups (*P = 0.004 < 0.01). (c) The expression of IL-37 mRNA in several cell lines detected by Q-PCR. (d) The expression of IL-37 protein (both pro-IL-37 and mat-IL-37) in several cell lines detected by Western blot.
Supplier Page from R&D Systems, a Bio-Techne Brand for Recombinant Human IL-37b/IL-1F7b Protein